AMYLYX PHARMACEUTICALS INC (AMLX) Stock Analyst Ratings
USA - NASDAQ:AMLX - US03237H1014 - Common Stock
13.6 USD
-0.33 (-2.37%)
13.6 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 86% to AMLX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 18.36. This target is 35% above the current price.
AMLX was analyzed by 16 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about AMLX.
In the previous month the buy percentage consensus was at a similar level.
AMLX was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-17 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-16 | Baird | Maintains | Outperform -> Outperform |
| 2025-10-03 | B of A Securities | Maintains | Buy -> Buy |
| 2025-09-16 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-09-15 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-28 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-10 | Goldman Sachs | Reiterate | Buy |
| 2025-06-24 | Guggenheim | Initiate | Buy |
| 2025-06-17 | Citigroup | Initiate | Buy |
| 2025-05-14 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-05-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-07 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-04-07 | Mizuho | Upgrade | Neutral -> Outperform |
| 2025-03-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-18 | Baird | Upgrade | Neutral -> Outperform |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-12 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-07-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-14 | Mizuho | Maintains | Neutral -> Neutral |
| 2024-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-11 | Baird | Maintains | Neutral -> Neutral |
| 2024-04-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-11 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-03-11 | Deutsche Bank | Maintains | Buy -> Buy |
| 2024-03-11 | Baird | Downgrade | Outperform -> Neutral |
AMYLYX PHARMACEUTICALS INC / AMLX FAQ
What is the price target for AMLX stock?
16 analysts have analysed AMLX and the average price target is 18.36 USD. This implies a price increase of 35% is expected in the next year compared to the current price of 13.6.
How do analysts rate AMYLYX PHARMACEUTICALS INC (AMLX)?
The consensus rating for AMYLYX PHARMACEUTICALS INC (AMLX) is 86.25 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover AMYLYX PHARMACEUTICALS INC (AMLX) stock?
The number of analysts covering AMYLYX PHARMACEUTICALS INC (AMLX) is 16.